Search results for " stroke"

showing 10 items of 328 documents

Impact of completeness of ascertainment of minor stroke on stroke incidence: implications for ideal study methods.

2013

Background and Purpose— Reliable comparisons of stroke incidence are important. To determine the impact of systematic assessment of patients referred with transient ischemic attack on the measured incidence and severity of stroke, we compared 2 population-based studies. Methods— Patients with first-ever stroke ascertained during 2006 through 2010 from the Dijon Stroke Registry and the Oxford Vascular (OXVASC) Study were studied. Both studies comply with the criteria for ideal incidence studies, but the OXVASC Study also systematically assessed all patients referred with transient ischemic attack. Stroke severity was measured by the National Institutes of Health Stroke Scale. Results— Among…

MalePediatricsmedicine.medical_specialtyStroke registryPopulationStroke severitySeverity of Illness IndexCohort StudiesStudy methodsEpidemiologymedicineHumansRegistriescardiovascular diseaseseducationAgedAged 80 and overAdvanced and Specialized Nursingeducation.field_of_studyStroke scalebusiness.industryIncidenceMinor strokeMiddle AgedHealth SurveysStrokeEnglandIschemic Attack TransientFemaleFranceNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke incidenceStroke; a journal of cerebral circulation
researchProduct

Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016

2018

Background: The lifetime risk of stroke has been calculated in a limited number of selected populations. We sought to estimate the lifetime risk of stroke at the regional, country, and global level using data from a comprehensive study of the prevalence of major diseases.Methods: We used the Global Burden of Disease (GBD) Study 2016 estimates of stroke incidence and the competing risks of death from any cause other than stroke to calculate the cumulative lifetime risks of first stroke, ischemic stroke, or hemorrhagic stroke among adults 25 years of age or older. Estimates of the lifetime risks in the years 1990 and 2016 were compared. Countries were categorized into quintiles of the sociode…

MalePercentileNutrition and DiseaseDisease030204 cardiovascular system & hematologyGlobal HealthSocioeconomic FactorGlobal Burden of Disease0302 clinical medicinepreventionVoeding en ZiekteCause of DeathGlobal healthStrokePOPULATIONCause of deathAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceMedicine (all)11 Medical And Health SciencesGeneral MedicineMiddle Agedlifetime riskstroke3142 Public health care science environmental and occupational health3. Good healthStrokeGBD 2016 Lifetime Risk of Stroke CollaboratorsFemaleBURDENLife Sciences & BiomedicineResearch ArticleHumanAdultRiskPopulationGlobal Burden of Disease (GBD)03 medical and health sciencesMedicine General & InternalAge DistributionGeneral & Internal MedicinemedicineHumansLife SciencePoint estimationcardiovascular diseasesSex DistributioneducationVLAGAgedScience & TechnologyHYPERTENSIONbusiness.industrymedicine.diseaseSocioeconomic Factorsbusiness030217 neurology & neurosurgeryRCDemography
researchProduct

Epidemiology of stroke in Europe and trends for the 21st century

2016

International audience; Despite major improvements in primary prevention and acute treatment over the last decades, stroke is still a devastating disease. At the beginning of the 21st century, the age-standardized incidence of stroke in Europe ranged from 95 to 290/100,000 per year, with one-month case-fatality rates ranging from 13 to 35%. Approximately 1.1 million inhabitants of Europe suffered a stroke each year, and ischemic stroke accounted for approximately 80% of cases. Although global stroke incidence is declining, rates observed in young adults are on the rise, thus suggesting a need for strategies to improve prevention. In addition, because of the ageing population, the absolute n…

MalePopulation ageingPediatricsmedicine.medical_specialtyLacunar strokeDijonDisease030204 cardiovascular system & hematologyLacunar stroke03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAcute careEpidemiologymedicineHumans30-day case-fatalityRecurrent strokeTransient ischemic attackStrokeAtrial-fibrillationDepression (differential diagnoses)business.industryIncidenceIncidence (epidemiology)General Medicine[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosismedicine.disease3. Good healthEuropeStrokeRisk-factorsCognitive impairmentPopulation registryFemalebusiness030217 neurology & neurosurgeryDemography
researchProduct

Risk of Stroke and Post-Stroke Adverse Events in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

2017

Background The risk and outcomes of stroke in patients with chronic obstructive pulmonary disease exacerbations (COPDe) remain unclear. We examined whether patients with COPDe faced increased risk of stroke or post-stroke outcomes. Methods Using Taiwan’s National Health Insurance Research Database, we identified 1918 adults with COPDe and selected comparison cohorts of 3836 adults with COPD no exacerbations and 7672 adults without COPD who were frequency matched by age and sex in 2000–2008 (Study 1). Stroke event was identified during 2000–2013 follow-up period. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of stroke associated with COPDe were calculated. In a nested cohor…

MalePulmonologyEconomicslcsh:MedicineSocial SciencesComorbidityVascular MedicinePulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsMedicine and Health SciencesOdds Ratio030212 general & internal medicinelcsh:ScienceStrokeAged 80 and overCOPDMultidisciplinaryHazard ratioMiddle AgedStrokeHospitalizationNeurologyResearch DesignPopulation SurveillanceDisease ProgressionFemaleCohort studyResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignChronic Obstructive Pulmonary DiseaseCerebrovascular DiseasesCardiologyTaiwanResearch and Analysis MethodsRisk Assessment03 medical and health sciencesHealth EconomicsInternal medicinemedicineHumansIntensive care medicineAdverse effectIschemic StrokeAgedRetrospective StudiesEpilepsybusiness.industrylcsh:RRetrospective cohort studyOdds ratioPneumoniamedicine.diseaseComorbidityrespiratory tract diseasesHealth CarePatient Outcome Assessment030228 respiratory systemlcsh:QAdverse EventsbusinessHealth InsurancePLoS ONE
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Normal Reference Ranges for Echocardiography: Rationale, study design, and methodology (NORRE Study)

2013

International audience; BACKGROUND: Availability of normative reference values for cardiac chamber dimensions, volumes, mass, and function is a prerequisite for the accurate application of echocardiography for both clinical and research purposes. However, due to the lack of consistency in current echocardiographic 'reference values', their use for clinical decision-making remains questionable. AIMS: The aim of the 'Normal Reference Ranges for Echocardiography Study (NORRE Study)' is to obtain a set of 'normal values' for cardiac chamber geometry and function in a large cohort of healthy Caucasian individuals aged over a wide range of ages (25-75 years) using both conventional and advanced e…

MaleRadiology Nuclear Medicine and ImagingMESH: Echocardiography DopplerLeftSex Factor030204 cardiovascular system & hematologyDoppler echocardiographyDoppler imagingMESH: Stroke VolumeMESH: Ventricular Function LeftVentricular Function Left030218 nuclear medicine & medical imagingHeart VentricleCohort Studies0302 clinical medicine[INFO.INFO-TS]Computer Science [cs]/Signal and Image ProcessingNuclear Medicine and ImagingVentricular FunctionAge FactorProspective StudiesProspective cohort studyMESH: Cohort StudiesMESH: Aged2D and 3D echocardiographyMESH: Middle Agedmedicine.diagnostic_testAnthropometryAge FactorsDopplerGeneral MedicinePulsedReference Standardsreference valuesMiddle AgedCardiac mechanicEchocardiography Doppler3. Good healthEuropeMESH: Echocardiography Doppler PulsedCardiac mechanicsEchocardiographyMESH: Reference Standards[SDV.IB]Life Sciences [q-bio]/BioengineeringFemaleRadiologyCardiology and Cardiovascular Medicine[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processingCohort study2D and 3D echocardiography; Cardiac mechanics; Chamber size and function; M-mode; reference values; Adult; Age Factors; Aged; Anthropometry; Cohort Studies; Echocardiography Doppler; Echocardiography Doppler Pulsed; Europe; Female; Heart Ventricles; Humans; Male; Middle Aged; Prospective Studies; Reference Standards; Sensitivity and Specificity; Sex Factors; Stroke Volume; Ventricular Function Left; Cardiology and Cardiovascular Medicine; Radiology Nuclear Medicine and ImagingHumanAdultmedicine.medical_specialtyHeart VentriclesM-modeChamber size and functionSensitivity and Specificity03 medical and health sciencesSex FactorsMESH: Sex FactorsMESH: Anthropometry[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansMedical physicsAgedMESH: Age FactorsEchocardiography Doppler PulsedReproducibilityMESH: Humansbusiness.industryreference valueMESH: AdultStroke VolumeMESH: MaleMESH: Prospective StudiesMESH: Sensitivity and SpecificitySurgeryClinical trialProspective StudieSample size determinationReference StandardObservational studyMESH: EuropeMESH: Heart VentriclesCohort StudiebusinessMESH: Female
researchProduct

Effect of segmental muscle vibration on upper extremity functional ability poststroke: A randomized controlled trial.

2019

Abstract Background: Upper extremity functional impairments are common consequences of stroke. Therefore, continuous investigation of effective interventions for upper extremity functions after stroke is a necessity. Segmental muscle vibration (SMV) is one of the interventions that incorporate sensory stimulation to improve motor cortical excitability. The aim of this study was to investigate the influence of 5-minute SMV application along with supervised physical therapy (SPT) on improving activities of daily living and motor recovery on the hemiparetic upper extremity in patients with stroke. Methods: A sample of 37 patients poststroke (29 males) was randomly allocated to either SPT contr…

MaleRange of Motionmedicine.medical_specialtyActivities of daily livingTreatment outcomeHemiplegiaVibrationlaw.inventionUpper Extremity03 medical and health sciences0302 clinical medicineEffective interventionsPhysical medicine and rehabilitationRandomized controlled triallawActivities of Daily LivingElbowHumansMedicineMuscle Strengthcardiovascular diseases030212 general & internal medicineFunctional abilityStrokeActivities of Daily Living; Aged; Elbow; Female; Hemiplegia; Humans; Male; Middle Aged; Muscle Strength; Muscle Tonus; Muscle Skeletal; Range of Motion Articular; Recovery of Function; Stroke; Stroke Rehabilitation; Treatment Outcome; Upper Extremity; Vibration; Physical Therapy ModalitiesPhysical Therapy ModalitiesAgedSettore M-EDF/01 - Metodi e Didattiche delle Attivita' MotorieMuscle vibrationbusiness.industryStroke RehabilitationSkeletalRecovery of FunctionGeneral MedicineMiddle Agedmedicine.diseaseStrokeTreatment OutcomeMuscle Tonus030220 oncology & carcinogenesisSettore M-EDF/02 - Metodi e Didattiche delle Attivita' SportiveMusclefunction segmental muscle vibration stroke upper extremityFemalebusinessRange of motionArticular
researchProduct

Anticoagulant drugs in noncompaction: A mandatory therapy?

2008

BACKGROUND: Noncompaction of left ventricular myocardium is a rare congenital cardiomyopathy resulting from an incomplete myocardial morphogenesis that leads to the persistence of the embryonic myocardium. This condition is characterized by a thin compacted epicardial and an extremely thickened endocardial layer with prominent trabeculations and deep intertrabecular recesses. It is not clear, in noncompaction of myocardium, whether intertrabecular recesses could be responsible for thrombi formation and thromboembolic complications. METHODS: The prevalence of stroke and echocardiographic finding of thrombus was evaluated in a continuous series of 229 patients (men and women) affected by nonc…

MaleRegistrieTime FactorsEmbolismAdministration OralHeart VentricleRisk FactorsRegistriesStrokeIschemic strokeAnticoagulantCongenital cardiomyopathyGeneral MedicineMiddle AgedStrokeAnticoagulant drugsCardiologycardiovascular systemFemaleAnticoagulant drugs noncompactionCardiomyopathiesCardiology and Cardiovascular MedicineHumanAdultHeart Defects Congenitalmedicine.medical_specialtyStroke etiologyTime Factormedicine.drug_classIsolated left ventricular noncompactionHeart Ventriclesanticoagulant; embolism; ischemic stroke; Isolated left ventricular noncompactionInternal medicineThromboembolismmedicineHumanscardiovascular diseasesThrombusNoncompactionCardiomyopathiebusiness.industryRisk FactorAnticoagulantAnticoagulantsInfantmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEmbolismIschemic strokeThrombuLeft ventricular myocardiumbusiness
researchProduct

Impact of pulmonary embolism on in-hospital mortality of patients with ischemic stroke

2020

Pulmonary embolism (PE) is a frequent complication in immobile stroke patients and an important cause of death in stroke patients. We aimed to investigate predictors of PE and the impact of PE on survival of ischemic stroke patients.Patients were selected by screening the German nationwide inpatient sample (2005-2017) for ischemic stroke (ICD-code I63) and stratified for occurrence of PE (ICD-code I26). Impact of PE on mortality and predictors for PE in ischemic stroke patients were analysed.Overall, 2,914,546 patients were hospitalized due to ischemic stroke (50.5% females; 69.3% aged ≥70 years) in Germany 2005-2017. Among these, 0.4% had PE and 7.2% died during hospitalization. In-hospita…

MaleResuscitationmedicine.medical_specialtymedicine.medical_treatmentBrain Ischemia03 medical and health sciences0302 clinical medicineGermanyInternal medicineHumansMedicineHospital Mortalitycardiovascular diseases030212 general & internal medicineAgedIschemic StrokeCause of deathIn hospital mortalitybusiness.industryMortality rateThrombolysismedicine.diseasePulmonary embolismStrokeNeurologyIschemic strokeCardiologyFemaleNeurology (clinical)Pulmonary EmbolismbusinessComplication030217 neurology & neurosurgeryJournal of the Neurological Sciences
researchProduct

CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke.

2009

Aim: Up-regulation of soluble CD40 ligand (sCD40L) and of monocyte chemoattractant protein-1 (MCP-1) has been found in diabetes and in patients with acute cerebral ischemia. We asked whether (i) the two molecules are similarly upregulated among non-lacunar and lacunar diabetic strokes and (ii) sCD40L and/or MCP-1 predict the risk of cardiovascular events in this setting.Methods: Ninety patients with type 2 diabetes mellitus presenting with an acute ischemic stroke (compared with 45 control subjects) were evaluated on admission and up to 36 months (median 24 months) after the event.Results: Diabetic patients with acute stroke had higher plasma CD40L and MCP-1 than controls (p<0.0001), wit…

MaleRiskCD40 ligand stroke diabetesmedicine.medical_specialtystrokeCD40L MCP-1Settore MED/09 - Medicina Internacerebral ischemia; chemokines; cytokines; diabetes mellitusCD40 LigandIschemiachemokinesDiseasecerebral ischemiaCohort StudiesDiabetes ComplicationsInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusMedicineCD40LHumanscardiovascular diseasesStrokeChemokine CCL2Ageddiabetesbusiness.industryProportional hazards modelBiochemistry (medical)Type 2 Diabetes MellitusMiddle Agedmedicine.diseasecytokinesSurgeryStrokeTreatment OutcomeQuartileGene Expression RegulationCardiologyRegression AnalysisFemaleCardiology and Cardiovascular MedicinebusinessCohort studyMCP-1
researchProduct